BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Shen YC, Hsu HC, Lin TM, Chang YS, Hu LF, Chen LF, Lin SH, Kuo PI, Chen WS, Lin YC, Chen JH, Liang YC, Chang CC. H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. J Clin Oncol 2022;:JCO2101802. [PMID: 35044851 DOI: 10.1200/JCO.21.01802] [Reference Citation Analysis]
2 Lin C, Kao J. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:5-14. [DOI: 10.1111/apt.14683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
3 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
4 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
5 Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol 2021;36:569-80. [PMID: 33709606 DOI: 10.1111/jgh.15415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Reference Citation Analysis]
7 Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Reference Citation Analysis]
8 Tsai MC, Lin CC, Chen DW, Liu YW, Wu YJ, Yen YH, Huang PY, Yao CC, Chuang CH, Hsiao CC. The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. Medicina (Kaunas) 2021;57:574. [PMID: 34199695 DOI: 10.3390/medicina57060574] [Reference Citation Analysis]
9 Mai RY, Wang YY, Bai T, Chen J, Xiang BD, Wu GB, Wu FX, Li LQ, Ye JZ. Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients. Cancer Manag Res. 2019;11:8799-8806. [PMID: 31632139 DOI: 10.2147/cmar.s213432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
10 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Kudo M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020;9:367-77. [PMID: 32999864 DOI: 10.1159/000507934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hsieh Y, Limquiaco JL, Lin C, Chen W, Lin S. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol 2019;44:1141-51. [DOI: 10.1007/s00261-018-1831-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
13 Hsiao P, Hsieh KC, Chen YS, Hsu CC, Lo GH, Li YC, Hsieh PM, Lin HY, Wu TC, Yeh JH, Lin CW. Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e16074. [PMID: 31232945 DOI: 10.1097/MD.0000000000016074] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Chang CY, Wei CY, Chen PH, Hou MC, Chao Y, Chau GY, Lee RC, Huang YH, Su YH, Wu JC, Su CW. The role of albumin-bilirubin grade in determining the outcomes of patients with very early-stage hepatocellular carcinoma. J Chin Med Assoc 2021;84:136-43. [PMID: 33433133 DOI: 10.1097/JCMA.0000000000000482] [Reference Citation Analysis]
15 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Reference Citation Analysis]
16 Shao YY, Wang SY, Lin SM; Diagnosis Group,., Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc 2021;120:1051-60. [PMID: 33199101 DOI: 10.1016/j.jfma.2020.10.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
17 Kuo F, Cheng T, Cheng Y, Wu C, Wang C. Effectiveness of multimodality treatment for hepatocellular carcinoma patients with portal vein thrombosis: A real world experience. Adv in Digestive Med. [DOI: 10.1002/aid2.13275] [Reference Citation Analysis]
18 Qi W, Zhang Q, Xu Y, Wang X, Yu F, Zhang Y, Zhao P, Guo H, Zhou C, Wang Z, Sun Y, Liu L, Xuan W, Wang J. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation. J Viral Hepat 2020;27:387-96. [PMID: 31755220 DOI: 10.1111/jvh.13236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chang YJ, Chen LJ, Chang YJ, Chen PD. Population-based matching comparison between radiofrequency ablation and percutaneous ethanol or acetic acid injection for hepatocellular carcinoma. Eur J Surg Oncol 2020;46:1703-10. [PMID: 32475629 DOI: 10.1016/j.ejso.2020.04.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Chiang H, Lee C, Hu T, Hung C, Wang J, Lu S, Lai H, Su W, Lin C, Peng C, Chen C. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int 2018;38:1997-2005. [DOI: 10.1111/liv.13889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Chen KT, Tsai KF, Leung HWC, Chan ALF, Wang SY, Liang HL, Tang SY, Chou CK, Chen HY, Chan SH, Li MF. Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience. Medicina (Kaunas) 2021;57:779. [PMID: 34440985 DOI: 10.3390/medicina57080779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Lee CW, Yu MC, Wang CC, Lee WC, Tsai HI, Kuan FC, Chen CW, Hsieh YC, Chen HY. Liver resection for hepatocellular carcinoma larger than 10 cm: A multi-institution long-term observational study. World J Gastrointest Surg 2021; 13(5): 476-492 [PMID: 34122737 DOI: 10.4240/wjgs.v13.i5.476] [Reference Citation Analysis]
23 Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One 2020;15:e0230005. [PMID: 32163475 DOI: 10.1371/journal.pone.0230005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Novick D, Rajan N, Wei A, Cheng R, Szende A, Baik R, Colman S. Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan. Value Health Reg Issues 2022;30:76-82. [PMID: 35278836 DOI: 10.1016/j.vhri.2022.01.001] [Reference Citation Analysis]
25 Bae BK, Park HC, Yoo GS, Choi MS, Oh JH, Yu JI. The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. Cancers 2022;14:2081. [DOI: 10.3390/cancers14092081] [Reference Citation Analysis]
26 Wei CY, Chen PC, Chau GY, Lee RC, Chen PH, Huo TI, Huang YH, Su YH, Hou MC, Wu JC, Su CW. Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. Ann Transl Med 2020;8:238. [PMID: 32309385 DOI: 10.21037/atm.2019.12.157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Wang S, Su T, Chen B, Liu C, Liu C, Yang H, Tseng T, Chen P, Kao J. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.01.005] [Reference Citation Analysis]
28 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
29 Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH, Wang JH. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2021;11:737767. [PMID: 34760699 DOI: 10.3389/fonc.2021.737767] [Reference Citation Analysis]
30 Cantaloube M, Castan F, Creoff M, Prunaretty J, Bordeau K, Michalet M, Assenat E, Guiu B, Pageaux GP, Ychou M, Aillères N, Fenoglietto P, Azria D, Riou O. Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4853. [PMID: 34638336 DOI: 10.3390/cancers13194853] [Reference Citation Analysis]
31 Su C, Fang K, Lee R, Liu C, Chen P, Lee P, Kao W, Huang Y, Huo T, Hou M, Lin H, Wu J. Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association 2020;119:610-20. [DOI: 10.1016/j.jfma.2019.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Kang H, Lee HW. Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients. Int J Gastrointest Interv 2021;10:183-8. [DOI: 10.18528/ijgii210046] [Reference Citation Analysis]
33 Chen CT, Lee HL, Chiou HL, Chou CH, Wang PH, Yang SF, Chou YE. Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development. PLoS One 2018;13:e0198967. [PMID: 29889892 DOI: 10.1371/journal.pone.0198967] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
34 Xing Y, Liu ZR, Yu W, Zhang HY, Song MM. Risk factors for post-hepatectomy liver failure in 80 patients. World J Clin Cases 2021; 9(8): 1793-1802 [PMID: 33748228 DOI: 10.12998/wjcc.v9.i8.1793] [Reference Citation Analysis]
35 Chuang KT, Wang SN, Hsu SH, Wang LT. Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity. Cancer Med 2021;10:5545-56. [PMID: 34173348 DOI: 10.1002/cam4.4094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Huang HC, Gatchalian LB, Hsieh YC, Chen WT, Lin CC, Lin SM. Real-time virtual sonography-assisted radiofrequency ablation in liver tumors with conspicuous or inconspicuous images or peritumoral landmarks under ultrasonography. Abdom Radiol (NY) 2021;46:2814-22. [PMID: 33388803 DOI: 10.1007/s00261-020-02875-y] [Reference Citation Analysis]
37 Ho SY, Hsu CY, Liu PH, Ko CC, Huang YH, Su CW, Lee RC, Hou MC, Huo TI. Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade. Cancers (Basel) 2020;12:E1130. [PMID: 32366000 DOI: 10.3390/cancers12051130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Wu CH, Lee YH, Liang PC, Hu RH, Shih TT, Ho MC. Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma. J Formos Med Assoc 2022:S0929-6646(21)00593-3. [PMID: 35033411 DOI: 10.1016/j.jfma.2021.12.026] [Reference Citation Analysis]
39 Liu L. Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy. Infect Agent Cancer 2020;15:8. [PMID: 32042307 DOI: 10.1186/s13027-020-0277-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Yang H. Fever is not good after transarterial chemoembolization for hepatocellular carcinoma. Adv in Digestive Med 2020;7:56-7. [DOI: 10.1002/aid2.13221] [Reference Citation Analysis]
41 Lee HL, Tsai JT, Chen CY, Lin YC, Ho CB, Ting LL, Kuo CC, Lai IC, Lin CY, Tang JH, Huang YM, Kao WY, Cheng SW, Shen CN, Chen SW, Chiou JF. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Ther Adv Med Oncol 2019;11:1758835919889002. [PMID: 31839809 DOI: 10.1177/1758835919889002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Li CH, Palanisamy K, Li X, Yu SH, Wang IK, Li CY, Sun KT. Exosomal tumor necrosis factor-α from hepatocellular cancer cells (Huh-7) promote osteoclast differentiation. J Cell Biochem 2021. [PMID: 34383347 DOI: 10.1002/jcb.30127] [Reference Citation Analysis]
43 Chen CN, Tsai YT, Lai JN. 8 years post-marketing surveillance between Asari Radix and hepatocellular carcinoma: Nationwide population-based evidence against an association. J Ethnopharmacol 2019;243:112094. [PMID: 31323301 DOI: 10.1016/j.jep.2019.112094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Liu CM, Huang BS, Yen YH, Wang YM, Huang EY, Hsu HC, Huang TT, Yang YH, Cheng JY. Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis. J Hepatocell Carcinoma 2021;8:963-73. [PMID: 34434903 DOI: 10.2147/JHC.S323302] [Reference Citation Analysis]
45 Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc 2018;7:e11234. [PMID: 30111528 DOI: 10.2196/11234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
46 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One 2021;16:e0244939. [PMID: 33439893 DOI: 10.1371/journal.pone.0244939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
49 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
50 Rim CH, Cheng J, Huang W, Kimura T, Lee V, Zeng Z, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology 2020;148:73-81. [DOI: 10.1016/j.radonc.2020.03.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
51 Liang Y, Chang C, Sheu M, Lin S, Chung C, Teng C, Suk F. The Antihistamine Deptropine Induces Hepatoma Cell Death through Blocking Autophagosome-Lysosome Fusion. Cancers 2020;12:1610. [DOI: 10.3390/cancers12061610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
52 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 69.0] [Reference Citation Analysis]
54 Lai HC, Lee MS, Lin C, Lin KT, Huang YH, Wong CS, Chan SM, Wu ZF. Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study. Br J Anaesth. 2019;123:151-160. [PMID: 31171343 DOI: 10.1016/j.bja.2019.04.057] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
55 Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Haruki U. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature. World J Clin Cases 2022; 10(8): 2591-2603 [DOI: 10.12998/wjcc.v10.i8.2591] [Reference Citation Analysis]
56 Huang YK, Yen CL, Shiu SI, Lee SW, Chang PY, Yeh HZ, Lee TY. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. PLoS One 2017;12:e0188999. [PMID: 29190692 DOI: 10.1371/journal.pone.0188999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
57 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Lee J, Han JW, Sung PS, Lee SK, Yang H, Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, Kwon JH, Jang JW, Kim CW, Nam SW, Oh JS, Chun HJ, Bae SH, Choi JY, Yoon SK. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study. J Clin Med 2021;10:4045. [PMID: 34575160 DOI: 10.3390/jcm10184045] [Reference Citation Analysis]
59 Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]